Narcolepsy
RecruitingEfficacy and Safety of ALKS 2680 and Alixorexton in Adults with Narcolepsy Type 1
- Disease:Narcolepsy
- Substances:Alks 2680
Germany- Participants:18–64 years · 65+ years
- Substances:Alks 2680
- Sponsor:Alkermes Inc.
Rare diseases
Investigational molecules
Locations
Back to Germany250 clinical trials in Bochum, Germany across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
Germany
GermanyThe busiest research cities in the country
What the registry says about research in the country
Clinical trials focusing on skin conditions, including studies for cutaneous lupus erythematosus, hidradenitis suppurativa, and plaque psoriasis. Novel therapeutic approaches are being evaluated to improve treatment outcomes for patients with chronic skin disorders.
Multiple studies are investigating new medications for moderate to severe cases of these conditions.
Innovative research in cancer treatment, particularly focusing on colorectal cancer, pancreatic cancer, gastric cancer, and non-small cell lung cancer. These trials are evaluating targeted therapies and combination treatments.
New therapeutic approaches combining immunotherapy with targeted treatments are being studied.
Studies focusing on heart failure prevention and chronic kidney disease management. Research includes innovative combination therapies and preventive approaches for high-risk patients.
Trials are evaluating new treatment combinations to improve patient outcomes.
Tell us about your condition – we search every trial in Europe and connect you with the right site.